CLASSICAL HODGKIN LYMPHOMA

This large international study tested whether children and teens with Hodgkin lymphoma could receive less radiation therapy without reducing their chance of being cured. Over 2,900 participants were randomly assigned to different chemotherapy intensities based on their disease st…

This study tested whether giving the drug brentuximab vedotin for up to a year after a stem cell transplant could help control Hodgkin lymphoma that had returned or not responded to treatment. 14 adults took part. The goal was to see if this approach could lower the chance of the…

This study tested a new drug combination (MK-4280A) against standard chemotherapy in 203 people with classical Hodgkin lymphoma that had returned or stopped responding to prior treatments, including PD-(L)1 therapy. The goal was to see if the new combination could delay cancer gr…

This early-phase study tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several types of advanced cancer. The goal was to see if blocking a molecule that can hide cancer from the immune system could make treatment more effective. Only 1…

This study tested an experimental drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to see if the drug could shrink or eliminate tumors. Participants received the drug by infusion, and resea…

This study tested a drug called tislelizumab in 46 people whose Hodgkin lymphoma had come back or stopped responding to other treatments. The goal was to see if the drug could shrink tumors. Many participants saw their tumors shrink or disappear, but the disease may still return,…

This study looked at 137 adults with newly diagnosed classical Hodgkin lymphoma to see if a specific genetic change (XPO1 E571K) found in their blood could signal whether cancer remains after chemotherapy. Researchers compared the blood test results with standard PET scans to mea…